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Abstract
Objective
To measure CSF levels of biomarkers reﬂecting microglia and astrocytes activation, neuro-
inﬂammation, and cerebrovascular changes and study their associations with the core bio-
markers of Alzheimer disease (AD) pathology (β-amyloid [Aβ] and tau), structural imaging
correlates, and clinical disease progression over time.
Methods
The study included cognitively unimpaired elderly (n = 508), patients with mild cognitive
impairment (MCI, n = 256), and patients with AD dementia (n = 57) from the longitudinal
Swedish BioFINDER cohort. CSF samples were analyzed for YKL-40, interleukin (IL)–6, IL-7,
IL-8, IL-15, IP-10, monocyte chemoattractant protein 1, intercellular adhesion molecule 1
(ICAM-1), vascular adhesion molecule 1 (VCAM-1), placental growth factor, and fms-related
tyrosine kinase 1 (Flt-1). MRI data were available from 677 study participants. Longitudinal
clinical assessments were conducted in control individuals and patients with MCI (mean
follow-up 3 years, range 1–6 years).
Results
CSF levels of YKL-40, ICAM-1, VCAM-1, IL-15, and Flt-1 were increased during the pre-
clinical, prodromal, and dementia stages of AD. High levels of these biomarkers were associated
with increased CSF levels of total tau, with the associations, especially for YKL-40, being
stronger in Aβ-positive individuals. The results were similar for associations between phos-
phorylated tau and YKL-40, ICAM-1, and VCAM-1. High levels of the biomarkers were also
associated with cortical thinning (primarily in the precuneus and superior parietal regions) and
with subsequent cognitive deterioration in patients without dementia as measured with Mini-
Mental State Examination (YKL-40) and Clinical Dementia Rating Sum of Boxes (YKL-40,
ICAM-1, VCAM-1 and IL-15). Finally, higher levels of CSF YKL-40, ICAM-1, and Flt-1
increased risk of development of AD dementia in patients without dementia.
Conclusions
Neuroinﬂammation and cerebrovascular dysfunction are early events occurring already at
presymptomatic stages of AD and contribute to disease progression.
From the Clinical Memory Research Unit (S.J., N.M., E.S., O.L., S.P., O.H.), Department of Clinical Sciences, Lund University; Department of Neurology (N.M., S.P.) and Memory Clinic
(E.S., O.H.), Skåne University Hospital; Institute of Neuroscience and Physiology (H.Z., K.B.), Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at the University
of Gothenburg; Clinical Neurochemistry Laboratory (H.Z., K.B.), Sahlgrenska University Hospital, Sweden; Department of Molecular Neuroscience (H.Z.), UCL Institute of Neurology;
and UK Dementia Research Institute at UCL (H.Z.), London.
Go to Neurology.org/N for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.
The Article Processing Charge was funded by Swedish Research Council.
This is an open access article distributed under the terms of the Creative Commons Attribution License 4.0 (CC BY), which permits unrestricted use, distribution, and reproduction in any
medium, provided the original work is properly cited.
Copyright © 2018 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. e867
β-Amyloid (Aβ) and tau pathology in Alzheimer disease (AD)
is associated with a number of cellular reactions in the sur-
rounding tissue. AD is accompanied by activation of microglia
and astrocytes1,2 that aﬀects the clearance and production of
Aβ42,3,4 development and propagation of tau pathology,5
exacerbates neurodegeneration, and inﬂuences disease pro-
gression and severity.6,7 Genome-wide association studies
have identiﬁed several single nucleotide polymorphisms in
immune-related genes that are linked to increased risk of AD.8
AD is also associated with cerebrovascular changes that have
been implicated in neuronal dysfunction and neuro-
degeneration.9 AD frequently co-occurs with cerebrovascular
disease10 and these conditions have common risk factors in-
cluding APOE e4, hyperlipidemia, obesity, and others.11 At
the same, studies have indicated that Aβ pathology may lead
to secondary vascular damage including white matter lesions,
microinfarcts, and microbleeds.12
Despite several lines of evidence supporting a role of neuro-
inﬂammation and cerebrovascular dysfunction in AD, further
research is needed to elucidate how these changes are linked
to Aβ and tau pathology and whether they represent an early
phenomenon driving neurodegeneration and clinical pro-
gression, or merely downstream bystander eﬀects of the dis-
ease. In the present study, we measured a panel of 11
inﬂammatory and vascular biomarkers in CSF of 508 cogni-
tively unimpaired elderly and 313 patients with mild cognitive
impairment (MCI) and AD dementia. We examined whether
these biomarkers were associated with Aβ and tau pathology,
cortical atrophy, rate of longitudinal cognitive decline, and
risk of AD.
Methods
Standard protocol approvals, registrations,
and patient consents
The study was approved by the Regional Ethics Committee in
Lund, Sweden, and the patients or their relatives gave written
informed consent.
Study participants
The study population included 315 cognitively normal el-
derly participants (recruited from the population-based
Malmo¨ Diet Cancer Study13), 449 patients with mild cog-
nitive complaints, and 57 patients with AD dementia en-
rolled consecutively at 3 memory outpatient clinics in
Sweden between 2010 and 2014 (the prospective and lon-
gitudinal Swedish BioFINDER study; bioﬁnder.se). In-
clusion criteria for cognitively normal elderly were (1) age
≥60 years, (2) Mini-Mental State Examination (MMSE)
28–30 points at the screening visit, (3) absence of cognitive
symptoms as evaluated by a physician, (4) ﬂuency in
Swedish, and (5) not fulﬁlling the criteria of MCI or any
dementia. Individuals with (1) signiﬁcant neurologic or
psychiatric disease (e.g., stroke, Parkinson disease, multiple
sclerosis, major depression), (2) signiﬁcant systemic illness
making it diﬃcult to participate, or (3) signiﬁcant alcohol
abuse or (4) who were refusing lumbar puncture were ex-
cluded. Cognitively normal elderly underwent clinical
assessments at baseline and 2-, 4-, and 6-year follow-up
visits. The patients with mild cognitive complaints were
thoroughly examined by physicians specialized in dementia
disorders. The inclusion criteria were (1) cognitive symp-
toms, (2) not fulﬁlling the criteria for dementia, (3) MMSE
24–30 points, (4) age 60–80 years, and (5) ﬂuent in
Swedish. The exclusion criteria were (1) cognitive impair-
ment that without doubt could be explained by another
condition (other than prodromal dementia), (2) severe
somatic disease, and (3) refusing lumbar puncture or neu-
ropsychological investigation. These criteria resulted in
a clinically relevant population where 193 individuals were
classiﬁed as subjective cognitive decline (SCD) and 256 as
MCI. The classiﬁcation was based on a neuropsychological
battery assessing the cognitive domains of verbal ability,
visuospatial construction, episodic memory, and executive
functions and the clinical assessment of a senior neuropsy-
chologist. In agreement with US National Institute on
Aging–Alzheimer’s Association guidelines, cognitively nor-
mal individuals and study participants with SCD were in-
cluded in the cognitively unimpaired control group.14
Patients with cognitive complaints underwent annual clin-
ical assessments during 6-year follow-up. Patients with AD
were required to meet the criteria for probable AD deﬁned
by National Institute of Neurological and Communicative
Disorders and Stroke–Alzheimer’s Disease and Related
Disorders Association.15 They were included when re-
ceiving their AD diagnosis and thereafter underwent annual
clinical assessments. Cognitive progression was measured
using the MMSE and Clinical Dementia Rating (CDR)
based on thorough and standardized patient and informant
rating scales, interviews, and cognitive tests. Study partic-
ipants were categorized into groups with normal (Aβ−) and
Glossary
Aβ = β-Amyloid; AD = Alzheimer disease; CDR = Clinical Dementia Rating; CDR-SB = Clinical Dementia Rating Sum of
Boxes; Flt-1 = fms-related tyrosine kinase 1; GLM = general linear model; ICAM-1 = intercellular adhesion molecule 1; IL =
interleukin; IP-10 = interferon-γ–induced protein 10;MCI = mild cognitive impairment;MCP-1 = monocyte chemoattractant
protein 1; MMSE = Mini-Mental State Examination; p-tau = phosphorylated tau; PlGF = placental growth factor; SCD =
subjective cognitive decline; t-tau = total tau; VCAM-1 = vascular adhesion molecule 1; VEGF = vascular endothelial growth
factor.
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pathologic (Aβ+) CSF signature using the CSF Aβ42/Aβ40
ratio cutoﬀ ≤0.1.16 Demographics are shown in table 1.
CSF sampling and analysis
Collection of lumbar CSF samples was performed at the 3
centers with participants nonfasting and the samples were
analyzed according to a standardized protocol.17 Following
collection, the samples were centrifuged (2,000 g, +4°C, 10
minutes), 1 mL was aliquoted into polypropylene tubes
(Sarstedt AG & Co., Nu¨mbrecht, Germany), and aliquots
were stored at −80°C. All CSF samples went through one
freeze–thaw cycle before the analysis when 200 μL were fur-
ther aliquoted into Lobind tubes (Eppendorf Nordic A/S,
Hørsholm, Denmark).
CSF concentrations of the neuroinﬂammatory and cerebro-
vascular biomarkers (interleukin [IL]–6, IL-7, IL-8, IL-15,
interferon-γ–induced protein 10 [IP-10], monocyte chemo-
attractant protein 1 [MCP-1], intercellular adhesion molecule
1 [ICAM-1], vascular adhesion molecule 1 [VCAM-1], pla-
cental growth factor [PlGF], and fms-related tyrosine kinase 1
[Flt-1]) were analyzed using ultrasensitive Mesoscale Dis-
covery immunoassay and a customized V-PLEX kit. These
biomarker assays were selected from the preconﬁgured
V-PLEX Neuroinﬂammation Panel 1 Human Kit (combining
proinﬂammatory, cytokine, chemokine, and angiogenesis
panels) if the intra-assay and interassay coeﬃcients of varia-
tion were below 20% and if the assays were sensitive enough
for CSF analysis in our test samples/runs. CSF samples were
analyzed with the customized kit according to the manu-
facturer’s recommendations with one modiﬁcation: for che-
mokine and proinﬂammatory panels, samples and calibrators
were incubated overnight at +4°C.
CSF concentration of YKL-40 (chitinase-3-like protein 1),
Aβ42, Aβ40, total tau (t-tau), and phosphorylated tau (p-tau)
were measured using ELISA kits according to the manu-
facturer’s recommendations (YKL-40, R&D Systems, Inc.,
Minneapolis, MN; Aβ42, Aβ40, t-tau, EUROIMMUN AG,
Lu¨beck, Germany; p-tau, Fujirebio, Ghent, Belgium).
All analyses were performed using one batch of reagents and
samples were randomized according to diagnosis across
plates/runs to minimize the eﬀects of run-to-run variation.
MRI
A total of 735 controls and patients withMCI underwentMRI
performed on a 3T Siemens (Erlangen, Germany) Trio sys-
tem equipped with a standard 12-channel head coil. A single
3TMRI scanner (SiemensMedical Solutions) was used for all
patients. Cortical thickness analysis modeling and volumetric
estimations of cortical and subcortical brain regions were
Table 1 Demographic and clinical data
Control–Aβ2, n = 362 Control–Aβ+, n = 146 MCI–Aβ2, n = 114 MCI–Aβ+, n = 142 AD, n = 57
Sex, F/M 206/156 85/61 36/78a,b 65/77c,d,e 34/23f
Age, y 71 (6) 73 (5)g 70 (6)b,c 72 (5)d,e 75 (5)a,f,h,i
MMSE 28.9 (1.1) 28.6 (1.3)g 27.4 (1.9)a,b 26.8 (1.7)a,b,j 21.9 (3.8)a,b,f,i
APOE 1or 2 «4 alleles, %k 22 60a 27b 71a,d,f 78a,d,f
Anti-inflammatory drugs, %l 13 14 8 10 9
Aβ42, pg/mL 650 (203) 392 (155)a 623 (237)b 352 (143)a,f 306 (101)a,b,f,m
Aβ40, pg/mL 4,550 (1,481) 5,469 (1,937)a 4,296 (1,723)b 5,109 (1,861)a,f 4,764 (1,600)d
Aβ42/Aβ40 0.146 (0.026) 0.073 (0.016)a 0.148 (0.028)b 0.070 (0.016)a,f 0.067 (0.017)a,d,f
t-tau, pg/mL 272 (73) 450 (146)a 285 (87)b 489 (183)a,f 576 (194)a,b,f,n
p-tau, pg/mL 47 (14) 74 (25)a 47 (15)b 78 (31)a,f 87 (32)a,f,h
Abbreviations: Aβ = β-Amyloid; AD = Alzheimer disease; MCI = mild cognitive impairment; MMSE = Mini-Mental State Examination; p-tau = phosphorylated
tau; t-tau = total tau.
Continuous data are shown as mean (SD). Demographic factors, clinical characteristics, and CSF biomarkers were compared using χ2 and Student t tests.
a p < 0.001 Compared to control–Aβ−.
b p < 0.001 Compared to control–Aβ+.
c p < 0.05 Compared to control–Aβ−.
dp < 0.05 Compared to control–Aβ+.
ep < 0.05 Compared to MCI–Aβ−.
f p < 0.001 Compared to MCI–Aβ−.
g p < 0.01 Compared to control–Aβ−.
h p < 0.01 Compared to control–Aβ+.
i p < 0.001 Compared to MCI–Aβ+.
j p < 0.01 Compared to MCI–Aβ−.
k APOE data are missing for 3 patients.
l Anti-inflammatory drugs data are missing for 1 patient.
m p < 0.05 Compared to MCI–Aβ+.
n p < 0.01 Compared to MCI–Aβ+.
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performed on structural T1 images with the FreeSurfer image
analysis package version 5.3 (surfer.nmr.mgh.harvard.edu/).
This software package was used for imaging intensity nor-
malization, removal of nonbrain tissues, segmentation of
cortical and subcortical brain regions into white and gray
matter, spherical surface-based intersubject registration,
which is based on the cortical surface curvature (sulci and
gyri), and, ﬁnally, an automated parcellation of the cortical
surface. FreeSurfer output was visually inspected for quality
control. Of the original 735 participants, 717 had MRI seg-
mentation from FreeSurfer. Quality control revealed 40 par-
ticipants with segmentation errors and thus 677 were included
in the ﬁnal analysis.
Statistical analysis
SPSS version 22 (IBM, Armonk, NY) and R version 3.3.118
were used for statistical analysis. Two cases showed ex-
tremely high levels of multiple analytes and increased pro-
tein levels in CSF and were excluded from the study. IL-6,
IL-8, and IP-10 were skewed (skewness 16.1, 9.1, and 14.1,
respectively) and therefore ln transformed values were used
in statistical analysis. Associations between CSF biomarkers
of neuroinﬂammation and cerebrovascular changes and
baseline characteristics (e.g., age, sex) were examined with
the Pearson correlation and Student t tests. Some study
participants were taking anti-inﬂammatory medications and
there were also diﬀerences in age, sex, and APOE genotype
between the diagnostic groups (table 1). Therefore, group
diﬀerences in the biomarker levels were ﬁrst tested with one-
way analysis of variance and, when statistically signiﬁcant,
were further investigated in univariate general linear models
(GLM) adjusting for the potential confounders with age, sex,
APOE genotype, and anti-inﬂammatory medications in-
cluded as covariates. For group comparisons, p values were
corrected using the Bonferroni method. Associations be-
tween CSF biomarkers and tau were assessed using linear
regression models. To determine whether the baseline bio-
marker levels were independent predictors of AD dementia,
we used Cox proportional hazard regression models. All
study participants were censored at their last follow-up visit
or diagnosis of dementia. Because CSF biomarker scales
diﬀered considerably, standardized variables (continuous or
tertiles) were used in Cox proportional hazard regression
models. Associations between biomarkers and longitudinal
MMSE and CDR Sum of Boxes (CDR-SB) were tested using
linear mixed-eﬀects models (with R v 3.2.3 and the lme4
package). These models had random intercepts and slopes
for time and an unstructured covariance matrix for the ran-
dom eﬀects, and included the interaction between time and
the biomarker as predictor. Associations between bio-
markers and volumetric estimates of subcortical grey matter
structures (corrected for total intracranial volume) and re-
gional cortical thickness were studied using linear regression
models adjusting for multiple comparisons with the false
discovery rate procedure at a q value of 0.05. All regression
models were adjusted for age, sex, and APOE genotype. The
Query Design Estimate Contrast tool was used for GLM
analysis at each vertex of the cortical surface. The model
included sex and APOE e4 carriers vs noncarriers as discrete
factors and age as nuisance variable and cortical thickness as
dependent variable. The results of the GLM analysis were
corrected for multiple comparisons at the cluster level using
the Monte Carlo simulation method for p cluster at p < 0.01
(z vertex 2.0).
Data availability
Anonymized data will be shared by request from any qualiﬁed
investigator for the sole purpose of replicating procedures and
results presented in the article and as long as data transfer is in
agreement with EU legislation on the general data protection
regulation.
Results
Associations with demographic data
In the whole cohort, all CSF neuroinﬂammatory and cere-
brovascular analytes except IL-6 correlated with age (data
available from Dryad) (table 1) (doi.org/10.5061/dryad.
5f82b32). The levels of IL-6, MCP-1, ICAM-1, VCAM-1, and
PlGF were higher in men whereas Flt-1 levels were higher in
women. There were no diﬀerences in YKL-40, IL-7, IL-8, IL-
15, and IP-10 between men and women or in any of the
biomarkers between APOE e4 carriers and noncarriers (data
available from Dryad) (table 1) (doi.org/10.5061/dryad.
5f82b32). Study participants taking anti-inﬂammatory medi-
cations had higher concentrations of IP-10 but did not diﬀer
in the levels of the other biomarkers from those not taking
anti-inﬂammatory medications (data available from Dryad)
(table 1) (doi.org/10.5061/dryad.5f82b32).
CSF biomarkers and amyloid pathology
To study possible associations between Aβ pathology and
CSF biomarkers of neuroinﬂammation and cerebrovascular
dysfunction, we ﬁrst examined the eﬀects of Aβ status on CSF
biomarker levels in GLM, covaried for clinical diagnosis. We
found that pathologic Aβ status was associated with higher
levels of YKL-40, ICAM-1, VCAM-1, IL-15, and Flt-1 (all p <
0.001) in both control and MCI groups, and the interaction
terms were negative (i.e., the eﬀect of CSF Aβ status on the
tested biomarkers was independent of clinical diagnosis). We
did not observe any eﬀect of Aβ status on the levels of IL-6, IL-
7, IL-8, PlGF, IP-10, or MCP-1.
To establish how early in the disease course neuroinﬂammation
and cerebrovascular changes might occur, we compared con-
trol individuals with normal Aβ status (control–/Aβ−) to study
participants with preclinical disease (controls with pathologic
Aβ, control–/Aβ+), prodromal disease (MCI with pathologic
Aβ status, MCI–Aβ+), and AD dementia. We also wanted to
establish if the CSF levels of the biomarkers were associated
with disease severity. For this, we studied diﬀerences in the
biomarkers between the control–Aβ+, MCI–Aβ+, and AD
groups. The results are summarized in ﬁgure 1. Compared with
the control–Aβ− group, the CSF levels of YKL-40, ICAM-1,
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VCAM-1, IL-15, and Flt-1 were increased in all groups with
pathologic Aβ status (control–Aβ+, MCI–Aβ+, and AD de-
mentia) but not in MCI–Aβ−. Furthermore, YKL-40 levels
were higher in AD dementia than in control–Aβ+ and MCI–
Aβ+. There were no diﬀerences in VCAM-1, Il-15, and Flt-1
levels between the groups with pathologic Aβ status
(control–Aβ+, MCI–Aβ+, and AD dementia). ICAM-1 was
higher in AD dementia than in control–Aβ+ and MCI–Aβ+,
but the diﬀerences between the groupswere confounded by the
eﬀects of age, sex, APOE e4 genotype, and anti-inﬂammatory
medications and were no longer signiﬁcant when these cova-
riates were included in the regression models. The rest of the
signiﬁcant ﬁndings were very similar when adjusting for the
covariates.
CSF biomarkers and tau
We next examined relationships between biomarkers of
neuroinﬂammation and cerebrovascular dysfunction (YKL-
40, ICAM-1, VCAM-1, IL-15, Flt-1) and CSF tau (t-tau and
p-tau), and whether these relationships diﬀered between
individuals with normal and pathologic Aβ status. In the
whole cohort, higher CSF levels of all biomarkers were as-
sociated with higher levels of t-tau and p-tau in both in Aβ-
negative and Aβ-positive groups (table 2). YKL-40, ICAM-1,
VCAM-1, IL-15, and Flt-1 interacted with Aβ status to predict
t-tau (YKL-40 p < 0.001; ICAM-1 p = 0.040; VCAM-1 p =
0.002; IL-15 p = 0.043; Flt-1 p = 0.001). Increased levels of
YKL-40, ICAM-1, VCAM-1, IL-15, and Flt-1 were associated
with higher levels of t-tau in Aβ-positive than Aβ-negative
Figure 1 CSF biomarkers of neuroinflammation and cerebrovascular changes in diagnostic groups
CSF levels of YKL-40 (A), intercellular
adhesion molecule 1 (ICAM-1) (B),
vascular adhesion molecule 1
(VCAM-1) (C), interleukin-15 (IL-15)
(D), and fms-related tyrosine kinase 1
(Flt-1) (E) in cognitively unimpaired
controls and patients with mild cog-
nitive impairment (MCI) with normal
(Ctrl–β-amyloid (Aβ)−, MCI–Aβ−,
Aβ42/Aβ40 >0.1) and pathologic
(Ctrl–Aβ+,MCI–Aβ+, Aβ42/Aβ40≤0.1)
CSF Aβ status and patients with Alz-
heimer disease (AD) dementia. For
comparison, CSF levels of total tau in
the same diagnostic groups are
shown in (F). Thedotted lines indicate
median levels in the Ctrl-Aβ− group.
p Values are from one-way analysis
of variance; statistical significance
was set to p < 0.0071 (0.05/7) to ac-
count for Bonferroni correction. The
significant findings were very similar
when adjusting for the covariates
(age, sex, APOE e4 genotype, andanti-
inflammatory medications), with the
exception of ICAM-1, for which there
were no differences between the
groups with pathologic CSF Aβ status
(Ctrl–Aβ+, MCI–Aβ+, and AD
dementia).
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people (ﬁgure 2A and table 2). We also found interaction
eﬀects between YKL-40, ICAM-1, VCAM-1, and Aβ status for
p-tau (p < 0.001, p = 0.024, and p = 0.011) (ﬁgure 2B and
table 2). Higher levels of IL-15 and Flt-1 were associated with
higher p-tau levels, but these associations did not depend on
Aβ status, i.e., were similar in Aβ-positive and Aβ-negative
study participants. The diﬀerences in slopes between Aβ-
positive and -negative individuals were particularly pro-
nounced for YKL-40. The associations with t-tau and p-tau
were similar in individual diagnostic groups (data available
from Dryad) (tables 3 and 4) (doi.org/10.5061/dryad.
5f82b32).
The signiﬁcant associations between the biomarkers and tau
were very similar when adjusting for the covariates (age, sex,
APOE e4 genotype, and anti-inﬂammatory medications)
(data available from Dryad) (table 4) (doi.org/10.5061/
dryad.5f82b32). Anti-inﬂammatory medications did not show
signiﬁcant eﬀects in any of the statistical tests and only age,
sex, and APOE e4 were included as covariates in all sub-
sequent statistical analysis.
CSF biomarkers and gray matter atrophy
We performed voxel-wise regression analysis, which showed
that high levels of CSF YKL-40 were associated with cortical
thinning mostly in parietal areas including precuneus, pos-
terior cingulate, and superior parietal cortices (ﬁgure 2C).
Similar patterns were observed for the other biomarkers with
further involvement of frontal regions (data available from
Dryad) (ﬁgure 1) (doi.org/10.5061/dryad.5f82b32). In
addition, higher levels of Flt-1 correlated with increased
cortical thickness in insula, temporal, and cingulate cortices.
In region of interest–based analyses, we found similar
associations between CSF biomarkers and cortical thickness
in some but not all areas that were signiﬁcant in the voxel-
wise regression models (data available from Dryad) (table 5)
(doi.org/10.5061/dryad.5f82b32). The most consistent
ﬁndings were associations between higher levels of the
biomarkers and cortical thinning in the precuneus and su-
perior parietal cortex (ﬁgure 2C) (data available from
Dryad) (ﬁgure 1 and table 5) (doi.org/10.5061/dryad.
5f82b32). When studying associations with subcortical gray
matter volumes, we found that high levels of YKL-40 (but
not other biomarkers) where associated with reduced vol-
umes of left and right caudate and left amygdala (β = −0.092,
p = 0.036; β = −0.124, p < 0.001; β = −0.102, p = 0.030; false
discovery rate–adjusted p values).
CSF biomarkers and AD progression
Associations between CSF biomarkers of neuroinﬂammation
and cognitive decline were assessed in control participants
and patients with MCI with repeated MMSE and CDR scores
available at each visit (n = 757, average follow-up 3 years,
range 1–6 years). Higher levels of YKL40 were associated
with lower MMSE at baseline and with more rapid longitu-
dinal decline in MMSE (table 3). Increased levels of YKL-40,
VCAM-1, and IL-15 were associated with higher baseline
CDR-SB. Increased levels of these biomarkers as well as
Table 2 Associations between CSF biomarkers of neuroinflammation and cerebrovascular dysfunction and tau by
β-amyloid (Aβ) status in the whole cohort
CSF Aβ+ CSF Aβ2
p Value for biomarker ×
Aβ status interactionB (SE) p Value B (SE) p Value
T-tau
YKL-40 1.18 (0.12) <0.001 0.41 (0.05) <0.001 <0.001
ICAM-1 41.6 (8.2) <0.001 24.0 (3.6) <0.001 0.040
VCAM-1 18.9 (2.9) <0.001 9.7 (1.2) <0.001 0.002
IL-15 55.4 (7.8) <0.001 38.3 (3.7) <0.001 0.043
Flt-1 6.7 (0.62) <0.001 4.4 (0.33) <0.001 0.001
P-tau
YKL-40 0.19 (0.02) <0.001 0.07 (0.01) <0.001 <0.001
ICAM-1 8.5 (1.3) <0.001 5.32 (0.65) <0.001 0.024
VCAM-1 3.6 (0.47) <0.001 2.3 (0.22) <0.001 0.011
IL-15 9.8 (1.3) <0.001 7.4 (0.66) <0.001 0.075
Flt-1 1.1 (0.10) <0.001 0.90 (0.06) <0.001 0.055
Abbreviations: AD = Alzheimer disease; Flt-1 = fms-related tyrosine kinase 1; ICAM-1 = intercellular adhesion molecule 1; IL-15 = interleukin-15; p-tau =
phosphorylated tau; t-tau = total tau; VCAM-1 = vascular adhesion molecule 1.
Results are from regression models with t-tau or p-tau as outcome measures and biomarkers, CSF Aβ status and interaction terms as regressors. Data are
shownas unstandardized coefficients B and standard error (SE). Every unit increase in biomarker levels (ng/mL for YKL-40, ICAM-1, and VCAM-1 andpg/mL for
IL-15 and Flt-1) corresponds to B unit equivalent increase in t-tau and p-tau levels.
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ICAM-1 were also associated with more rapid longitudinal
increase in CDR-SB (table 3).
Follow-up diagnosis was available from 728 study partic-
ipants who were cognitively unimpaired or had MCI at
baseline, of whom 115 (15.8%) progressed to AD dementia
(average follow-up 3 years, range 1–6 years). Cox regression
analysis including age, sex, and APOE e4 as covariates
showed that YKL-40, ICAM-1, and Flt-1, but not VCAM-1
and IL-15, were independent predictors of time to AD di-
agnosis (table 4). Compared to the lowest tertiles, the
highest tertiles of YKl-40 (p = 0.005), ICAM-1 (p = 0.001)
Table 3 Associations between baseline CSF biomarker levels and cognition
Biomarkers
MMSE CDR-SB
Baseline Time Baseline Time
β (SE) p β (SE) p β (SE) p β (SE) p
YKL-40 −0.18 (0.06) 0.004 −0.14 (0.05) 0.004 0.07 (0.03) 0.039 0.17 (0.03) <0.001
ICAM-1 −0.05 (0.07) 0.428 −0.06 (0.05) 0.185 0.03 (0.03) 0.371 0.09 (0.04) 0.010
VCAM-1 −0.09 (0.07) 0.194 −0.05 (0.05) 0.248 0.11 (0.03) 0.001 0.09 (0.03) 0.014
IL-15 −0.06 (0.07) 0.367 −0.04 (0.05) 0.387 0.09 (0.03) 0.007 0.09 (0.04) 0.015
Flt-1 −0.09 (0.06) 0.135 −0.04 (0.05) 0.359 0.03 (0.03) 0.302 0.06 (0.03) 0.078
Abbreviations: CDR-SB = Clinical Dementia Rating Sum of Boxes; Flt-1 = fms-related tyrosine kinase 1; ICAM-1 = intercellular adhesion molecule 1; IL-15 =
interleukin-15; MMSE = Mini-Mental State Examination; VCAM-1 = vascular adhesion molecule 1.
Associations of MMSE and CDR-SB scores (baseline and longitudinal) and individual biomarkers (standardized concentrations) were examined using linear
mixed-effects models that included age, sex, and APOE e4 as covariates.
Figure 2 CSF biomarkers of neuroinflammation and cerebrovascular changes, CSF tau, and cortical atrophy
(A, B) Association between CSF YKL-40 and total tau (t-tau) and CSF YKL-40 and phosphorylated tau (p-tau), respectively, in study participants with normal
(β-amyloid [Aβ]−) and pathologic (Aβ+) CSF status. Unstandardized B coefficients and p values for slopes are from linear regression models. The results were
very similar when adjusting for the covariates (age, sex, APOE e4 genotype, and anti-inflammatorymedications). (C) Associations between YKL-40 and cortical
thickness. Voxel-wise regression analysis corrected for age, sex, and APOE e4.
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and Flt-1 (p = 0.007), but not the middle tertiles, were
associated with increased risk of AD dementia (ﬁgure 3).
Discussion
We found that CSF levels of 5 biomarkers of neuro-
inﬂammation and cerebrovascular dysfunction (YKl-40,
ICAM-1, VCAM-1, IL-15, and Flt-1) were increased in AD
already during the preclinical and prodromal stages. These
biomarkers were associated with CSF tau, especially in Aβ-
positive individuals. Further, increased concentrations of the
biomarkers correlated with cortical thinning in the precuneus
and superior parietal cortex. Finally, the longitudinal data
suggested that higher levels of the neuroinﬂammatory and
cerebrovascular biomarkers were associated with cognitive
decline and increased risk of subsequent development of AD.
YKL-40 is a secreted glycoprotein that in the CNS is
expressed by microglia and astrocytes19,20 and is considered
one of the most promising biomarkers of neuroinﬂammation
in AD. Our ﬁndings on YKL-40 agree with previous data
showing increased CSF levels of this protein in preclinical,
prodromal, and dementia stages of AD.21–24 A recent meta-
analysis conﬁrmed elevated levels of YKL-40 in AD dementia,
although the association with AD was moderate compared
with the core CSF AD biomarkers Aβ42, t-tau, and p-tau.25
Earlier studies have indicated that CSF YKL-40 is associated
with tau pathology, since it may identify individuals with ab-
normal tau levels in CSF.21,26
We also showed that other CSF biomarkers of neuro-
inﬂammation and cerebrovascular dysfunction, including
ICAM-1, VCAM-1, IL-15, and Flt-1, were associated with Aβ
pathology, e.g., their levels were elevated in individuals with
pathologic CSF Aβ status. ICAM-1 and VCAM-1 are adhe-
sion molecules that are upregulated in endothelial cells under
inﬂammatory conditions.27 In postmortem tissue from
patients with AD, increased expression of ICAM-1 has been
detected in plaques and astrocytes around plaques.28 High
levels of ICAM-1 in temporal and cingulate cortices have
been shown to correlate with larger Aβ plaque and neuroﬁ-
brillary tangle loads in Lewy body disorder.29 Il-15 is a pleio-
tropic cytokine produced by many diﬀerent cell types
that regulates development, survival, and function of
peripheral lymphocytes.30 While IL-15 could be found in both
microglia and astrocytes, high expression by astrocytes has
been shown to exacerbate tissue damage in multiple sclerosis
and following brain ischemia.31,32 Flt-1 is one of the main
receptors of the vascular endothelial growth factor (VEGF)
family widely expressed in the vascular system.33 Apart from
its role in the regulation of angiogenesis, Flt-1 (together with
other members of VEGF family) has been implicated in glial
cell development and adult neurogenesis.34 In animal models
of cerebral ischemia, expression of Flt-1 is increased in
astrocytes, endothelial cells, and neurons.35 Interestingly,
upregulation of Flt-1 has been observed in the entorhinal
cortical sections from human AD brain and in human
microglia cells following treatment with Aβ42.36 One study
has previously reported no diﬀerence in serum Flt-1 levels
between patients with AD and healthy controls.37 Earlier
investigations that have measured CSF and blood levels of
ICAM-1, VCAM-1, and IL-15 in AD have produced con-
ﬂicting results.38–42 This inconsistency in results could be
partly due to heterogeneity of sample populations, various
confounding factors, and small sample sizes. In the present
study, using a large cohort of well-characterized patients, we
show increased levels of ICAM-1, VCAM-1, IL-15, and Flt-1in
AD at the preclinical, prodromal, and dementia stage, in-
dicating that neuroinﬂammatory pathways are activated early
in the disease course. These ﬁndings are in keeping with
a recent report demonstrating that serum and CSF neuro-
inﬂammation biomarker signatures that included ICAM-1,
VCAM-1, IL-15, and Flt-1 could identify individuals who had
AD CSF proﬁle (abnormal p-tau/Aβ42 ratio) in a group of
patients with MCI.43 Of note, there was a considerable
overlap in the CSF levels of YKL-40, ICAM-1, VCAM-1, IL-
15, and Flt-1 between diﬀerent groups in our study, sug-
gesting that ADmight be accompanied by neuroinﬂammation
and cerebrovascular dysfunction in a subpopulation of
patients. Future investigations assessing longitudinal changes
in the biomarker levels are warranted in order to further clarify
the roles of neuroinﬂammation and cerebrovascular dys-
function in AD progression including the development of tau
pathology.
Previous studies have shown that higher CSF YKL-40 was
associated with higher CSF tau, supporting a link between
neuroinﬂammation and neurodegeneration.21 Accordingly,
YKL-40 could distinguish patients with tau pathology from
healthy controls.26 Here we report correlations between tau
and several biomarkers of neuroinﬂammation and cerebro-
vascular dysfunction (YKL-40, ICAM-1, VCAM-1, IL-15, and
Flt-1). Notably, the correlations were stronger in individuals
with abnormal levels of CSF Aβ, indicating that the associa-
tions among neuroinﬂammatory, cerebrovascular, and
Table 4 Cox proportional hazards model of time to
Alzheimer disease (AD) dementia diagnosis
Variable Hazard ratio (95% CI), p value
YKL-40 1.41 (1.17–1.71), <0.001
ICAM-1 1.26 (1.04–1.54), 0.019
VCAM-1 1.23 (0.99–1.53), 0.066
IL-15 1.15 (0.96–1.38), 0.128
Flt-1 1.29 (1.10–1.52), 0.002
Abbreviations: CI = confidence interval; Flt-1 = fms-related tyrosine kinase 1;
ICAM-1 = intercellular adhesionmolecule 1; IL-15 = interleukin-15; VCAM-1 =
vascular adhesion molecule 1.
Associations of individual biomarkers (standardized concentrations) with
time to AD dementia diagnosis were examined using separate models that
included age, sex, and APOE e4 as covariates. Hazard ratios represent fold
increase in risk of AD for each 1+SD increase in biomarker levels.
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neurodegenerative processes may be aggravated in the pres-
ence of Aβ pathology. The diﬀerence in the slopes was more
pronounced for YKL-40 than for the other biomarkers (tables
2). A possible explanation for this ﬁnding could be that YKL-
40 continued to increase with disease progression and reached
its highest levels in AD dementia, whereas there were no
diﬀerences in the levels of the other biomarkers among Aβ-
positive controls, patients with prodromal AD, and patients
with AD dementia. Thus, these data support the hypothesis
that YKL-40 is associated with AD-related tau pathology in
individuals with abnormal Aβ deposition.
High CSF levels of neuroinﬂammatory biomarkers correlated
with cortical thinning predominantly in the precuneus and
superior parietal cortex, but not in temporal areas, as has been
reported for YKL-40 in a relatively smaller study.44 Both the
precuneus and superior parietal cortex are parts of AD cortical
signature that includes a set of cortical regions with consistent
pattern of atrophy across diﬀerent disease stages.45 In-
terestingly, the precuneus is one the nodes of the default
mode network, where early deposition of Aβ occurs.46 Of
relevance, PET studies have indicated increased microglia
activation in the precuneus and parietal cortex in AD.47,48
In patients without dementia, higher levels of YKL-40 were
associated with more rapid changes in MMSE and CDR-SB.
At the same time, higher CSF levels of YKL-40, ICAM-1,
VCAM-1, and IL-15 were related to more rapid increase in
CDR-SB. Further, higher levels of the biomarkers were as-
sociated with increased risk of future AD. Two earlier reports
have found that YKL-40 predicted progression to AD.22,49
Here we corroborate these ﬁndings in a considerably larger
Figure 3 CSF biomarkers of neuroinflammation and cerebrovascular changes and progression to Alzheimer disease (AD)
Kaplan-Meier curves of progression from cognitively normal and mild cognitive impairment (MCI) to AD for tertiles of YKL-40 (A), intercellular adhesion
molecule 1 (ICAM-1) (B), and fms-related tyrosine kinase 1 (Flt-1) (C).
Neurology.org/N Neurology | Volume 91, Number 9 | August 28, 2018 e875
cohort. Moreover, we show that not only YKL-40 but also
other biomarkers of neuroinﬂammation and cerebrovascular
dysfunction are associated with cognitive impairment, thus
suggesting that multiple neuroinﬂammatory and cerebrovas-
cular factors might contribute to disease progression.
We demonstrate that AD is accompanied by longstanding
changes in CSF levels of neuroinﬂammatory and cerebro-
vascular biomarkers, starting already at preclinical disease
stages. These changes most likely reﬂect neuroinﬂammation
and cerebrovascular dysfunction in the brain and our data
indicate that these pathologic processes may contribute to tau
pathology, neurodegeneration, cortical atrophy, and increased
risk of AD dementia. Thus, our study provides evidence of the
role of neuroinﬂammation and cerebrovascular dysfunction in
AD and oﬀers potential targets for novel therapeutic
interventions.
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